New Approach To Treating Anthrax Significantly Improves Survival Rates

Armen Hareyan's picture
Advertisement

Anthrax Disease

Results of two Human Genome Sciences animal studies demonstrated the life-saving potential of its human monoclonal antibody drug ABthrax (raxibacumab). The results show that a single dose of ABthrax, administered without concomitant antibiotics, improved survival rates by up to 64 percent when administered after animals were symptomatic for anthrax disease as a result of inhalation exposure to massively lethal doses of anthrax spores.

Advertisement